These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2138477)

  • 1. Weekly Adriamycin vs. 4-epidoxorubicin every second week in advanced breast cancer. A randomized trial. The Norwegian Breast Cancer Group.
    Gundersen S; Kvinnsland S; Klepp O; Lund E; Høst H
    Eur J Cancer; 1990 Jan; 26(1):45-8. PubMed ID: 2138477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems.
    Ebbs SR; Saunders JA; Graham H; A'Hern RP; Bates T; Baum M
    Acta Oncol; 1989; 28(6):887-92. PubMed ID: 2692652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial.
    Gasparini G; Dal Fior S; Panizzoni GA; Favretto S; Pozza F
    Am J Clin Oncol; 1991 Feb; 14(1):38-44. PubMed ID: 1987737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intra-arterial infusion chemotherapy of advanced breast cancer--effects and side effects of adriamycin, 4'-epi-adriamycin and THP-adriamycin].
    Toda K; Asaishi K; Okazaki M; Okazaki Y; Okazaki A; Sato H; Mikami T; Watanabe Y; Hayasaka H; Narimatsu E
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3011-4. PubMed ID: 2782905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial.
    Gundersen S; Kvinnsland S; Klepp O; Kvaløy S; Lund E; Høst H
    Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1431-4. PubMed ID: 3595668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
    Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
    Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
    Rozencweig M; ten Bokkel Huinink W; Cavalli F; Bruntsch U; Dombernowsky P; Høst H; Bramwell V; Renard G; Van Glabbeke M; Decoster G
    J Clin Oncol; 1984 Apr; 2(4):275-81. PubMed ID: 6584561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
    Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
    Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study.
    Gebbia V; Blasi L; Borsellino N; Caruso M; Leonardi V; Agostara B; Valenza R
    Anticancer Res; 2003; 23(1B):765-71. PubMed ID: 12680181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group.
    Gundersen S; Hannisdal E; Lundgren S; Wist E
    Eur J Cancer; 1994; 30A(12):1775-8. PubMed ID: 7880604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma.
    Lawton PA; Spittle MF; Ostrowski MJ; Young T; Madden F; Folkes A; Hill BT; MacRae K
    Clin Oncol (R Coll Radiol); 1993; 5(2):80-4. PubMed ID: 8481365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
    Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
    J Clin Oncol; 1993 Mar; 11(3):467-73. PubMed ID: 8445422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
    Beretta G; Locatelli C; Tabiadon D; Labianca R; Fraschini P; Luporini G
    Oncology; 1987; 44(1):6-12. PubMed ID: 2436124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly taxane-anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial.
    Tan QW; Luo T; Zheng H; Tian TL; He P; Chen J; Zeng HL; Lv Q
    Chin J Cancer; 2017 Mar; 36(1):27. PubMed ID: 28270181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II study of epirubicin on breast cancer: a cooperative group study].
    Tominaga T; Kitamura M; Nomura Y; Abe O; Enomoto K; Ikeda T; Izuo M; Iino Y; Taguchi T; Tamura K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2187-92. PubMed ID: 3459397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intra-arterial infusion chemotherapy in the treatment of advanced breast cancer--doxorubicin versus epirubicin].
    Yayoi E; Furukawa J; Takatsuka Y; Kobayashi T; Aikawa T; Maeura Y; Kaji M; Kotsuma Y
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1621-4. PubMed ID: 1530320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.